Exercise and liraglutide tested for blood vessel health in type 2 diabetes
Tests exercise, liraglutide, or both in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)
Key facts
- Where
- Charlottesville, United StatesSee the site
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 21-60 with type 2 diabetes who are on stable diabetes pills and have never used GLP-1 or DPP4 drugs.
- Age
- 21 to 60 years
- Sex
- Women and men can join.
- Disease stage
- Type 2 diabetes with A1C of 8.5% (69 mmol/mol) or lower.
- Earlier treatment
- Never on GLP-1RA (for example exenatide, liraglutide) or DPP4I (for example Sitaglipton). On a stable dose of oral hypoglycemic agents and other medications for more than 4 months.
- Biomarker or test result
- A1C of 8.5% (69 mmol/mol) or lower.
Main reasons for not taking part
- Taking insulin
- Smoking now or in the past 6 months
- Blood pressure above 160/90 or BMI above 35
- Heart failure, heart disease, severe lung disease, liver or kidney disease, or any vascular disease such as heart attack or stroke
- Pregnant or breastfeeding
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 60 years old?
Source: NCT03883412, who can take part
Where in United States
- University of VirginiaCharlottesville, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Virginia
- Trial code
- NCT03883412
- Record updated
- 12 August 2026
- Original description
The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and muscle capillary blood volume, improves vascular function in the larger conduit vessels, and enhances insulin's metabolic action in humans with Type 2 diabetes. Subjects will be randomized to one of the three groups: exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 16 weeks of intervention.Read full original descriptionShow less
Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)
The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and muscle capillary blood volume, improves vascular function in the larger conduit vessels, and enhances insulin's metabolic action in humans with Type 2 diabetes. Subjects will be randomized to one of the three groups: exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 16 weeks of intervention.
Inclusion: Age 21-60; A1C ≤ 8.5%; Never on GLP-1RA (eg: exenatide, liraglutide) or DPP4I ( eg: Sitaglipton); On stable dose of oral hypoglycemic agents >4 months; On stable dose of other medications for >4 months.
Exclusion: Family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome; History of congestive heart failure, ischemic heart disease, severe pulmonary disease, liver or kidney disease; Any vascular disease such as myocardial infarction, stroke, peripheral vascular disease; Known hypersensitivity to perflutren (contained in Definity); Taking Insulin; Smoking presently or in the past 6 months; BP >160/90; BMI >35; Presence of an intracardiac or intrapulmonary shunt (we will screen for this by auscultation during the physical exam by PI); Pregnant or breastfeeding.